Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

Xiaoxian Zhao,1 Shweta Singh,2 Cecile Pardoux,2 Jingsong Zhao,2 Eric D. Hsi,1 Arie Abo,2 and Wouter Korver2

1Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, and 2Nuvelo, Inc. San Carlos, CA, USA


Online Supplementary Figure S1. CLL-1 expression in AML cell lines and primary cells. (A) Quantitative flow cytometry analysis of a panel of AML-derived cell lines. (B) Western blot analysis of whole cell lysates for CLL-1 expression using anti-CLL-1 monoclonal antibody. (C) Immunohistochemical staining of blasts in AML bone marrow clot compared to staining in normal bone marrow. (D) Summary of CLL-1 expression analysis of peripheral blood from ten normal donors. (E) Flow cytometry analysis of CLL-1 expression of normal bone marrow using CD45 antibody to identify cell types. (F) Expression of CLL-1 in CD34+/CD38- leukemic stem cells.
Online Supplementary Figure S2. Comparison of CLL-1 expression with CD33 expression. (A) CD33 and CLL-1 expression in normal blood; bars represent the average results from five donors. (B) CD33 and CLL-1 expression in AML blasts and CD34+/CD38– leukemic stem cells; individual cases are represented by dots.

Online Supplementary Table S1. Summary of information on patients' samples analyzed in this study, including classification, cytogenetic data and expression of CLL-1 and CD33.